Skip to main content

23andMe’s Plan to Overcome FDA Concerns Over DNA Tests MIT Technology Review

By August 8, 2014News
23andme-logo

23andme-logoAnne Wojcicki bounds into a conference room in Mountain View, California, straight from a five-mile ride from home on an elliptical bike. The 40-year-old cofounder and CEO of the consumer genetic testing firm 23andMe is breathless, and not just because of the workout. On this warm day in mid-June, Wojcicki is “super-excited” about an announcement scheduled for two days hence: the Food and Drug Administration has agreed to review a health-related genetic report the company wants to make available to customers. 

{iframe}http://www.technologyreview.com/news/529006/23andme-tries-to-woo-the-fda/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.